Enabling Human Connectivity: Phantom Neuro Merges Human Augmentation and IoT
Cutting Edge Human-Machine Interface Startup to
"We're doing things differently in looking beyond current standards, like Bluetooth, which has limitations to operating within an individual's personal space," said Dr.
The Internet of Things had a similar need for high-bandwidth, swift data transmission within an individual's personal space, but without the constraining requirement of energy efficiency. Historically, this has limited IoT technologies' relevance to implantable medical systems that require small form factors.
Silicon Labs' family of Wi-Fi devices provides a Wi-Fi system tailored to efficiently manage high-bandwidth data with low power consumption, allowing Phantom Neuro to be the first of its kind to harness IoT Wi-Fi technology for its implantable medical system, expediting Phantom's cutting-edge human augmentation mission.
"For a solution that brings life changing mobility for individuals with limb differences, Phantom Neuro needs connectivity that just works," said
In addition to selecting Silicon Labs technology, Phantom Neuro has also participated in the company's IoT For Good Developer Stories initiative, to reflect on the multitudinous benefits of IoT related to patient care and outcomes.
About Phantom Neuro
Phantom is a neurotechnology company, spun out of a lab at the Johns Hopkins University School of Medicine, that is developing the world's first minimally invasive muscle-machine interface for control of prosthetic limbs and robotic exoskeletons. Learn more at www.phantomneuro.com
CONTACT
[email protected]
View original content to download multimedia:https://www.prnewswire.com/news-releases/enabling-human-connectivity-phantom-neuro-merges-human-augmentation-and-iot-301982499.html
SOURCE Phantom Neuro Inc.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- SCIA Hosts the First FDI Moot Global Finals in China, Strengthening Shenzhen's Position as a Global Arbitration Hub
- PureTech Presents Phase 1b Results for LYT-200 in Relapsed/Refractory (R/R) High-Risk Myelodysplastic Syndromes (HR-MDS) and Acute Myeloid Leukemia (AML) at ESMO 2026
- ASICS Opens Its First Industry-Academia R&D Lab for Running Innovation with the University of Michigan
Create E-mail Alert Related Categories
PRNewswire, Press ReleasesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!





Tweet
Share